Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-Mouse PD-L1 & OX40 Bispecific Antibody (Iv0244)

Catalog #:   VME43201 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG
Applications: FuncS
Accession: Q9EP73 & P47741
Overview

Catalog No.

VME43201

Species reactivity

Mouse

Host species

Mouse

Isotype

IgG

Clonality

Monoclonal

Target

Bispecific, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274, Cd274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Tumor necrosis factor receptor superfamily member 4, OX40 antigen, OX40L receptor, CD134, Tnfrsf4, Ox40, Txgp1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9EP73 & P47741

Applications

FuncS

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0244

Data Image
References

Development of a prognostic immune cell-based model for ovarian cancer using multiplex immunofluorescence., PMID:40537823

Real-life Experience of Rare Hepatoid Adenocarcinomas of the Lung: A Large Retrospective French Cohort., PMID:40537320

Xeno-free alternatives to the use of fetal bovine serum in head and neck cancer explant culture., PMID:40537045

Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?, PMID:40536609

Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells., PMID:40536473

Palmitoylation-driven immune dysregulation and prognostic signature in low-grade glioma: a multi-omics and functional validation study., PMID:40535771

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)., PMID:40535732

First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis., PMID:40535117

Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations., PMID:40535092

Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression., PMID:40535088

Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy., PMID:40535067

F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies., PMID:40534867

Janus kinase and signal transducer and activator of transcription inhibitors in type 1 diabetes and immune checkpoint-related diabetes: current status and future perspectives., PMID:40534861

Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients., PMID:40534853

A microfluidic tumor-on-chip platform deciphers hypoxia-driven FOXO3a/PD-L1 signaling in gastric cancer immunotherapy resistance., PMID:40534828

The PD-1/PD-L1 pathway and Epstein-Barr virus., PMID:40533842

Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort., PMID:40533655

PDHA1 Orchestrates Hepatocellular Carcinoma Progression Through LINC00607-Mediated Regulation of Cuproptosis and Immune Evasion., PMID:40533619

Proteasome Inhibition Induces IRF1 Downstream Molecules Independently of JAK Activity in Cancers., PMID:40533173

Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis., PMID:40532761

Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data., PMID:40532262

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer., PMID:40532178

Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion., PMID:40532063

[Another sight at Gastric Cancer Molecular Classification: novel subtypes based on expression of CDX-2, E-cadherin, Epstein-Barr virus RNAs, MMR proteins]., PMID:40531557

Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma., PMID:40531258

PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-Mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis., PMID:40531080

Tumor-Associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers., PMID:40530506

Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death., PMID:40530421

Therapeutic potential of adenosine receptor modulators in cancer treatment., PMID:40530308

Prognostic value of lactate dehydrogenase to albumin ratio in first-line chemoimmunotherapy for locally advanced or metastatic non-small cell lung cancer., PMID:40530119

Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study., PMID:40529756

Integrated pan-cancer analysis of ADM's role in prognosis, immune modulation and resistance., PMID:40529377

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study., PMID:40529375

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging., PMID:40529364

Site-Selective Anti-PD-L1 Antibody-MMAE Conjugate for Enhanced NSCLC Therapy., PMID:40529092

Real-World Survival Outcomes of Patients With High PD-L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy., PMID:40528544

HAPIR: a refined Hallmark gene set-based machine learning approach for predicting immunotherapy response in cancer patients., PMID:40527973

LASIP: Light-Activated STING Immunotherapeutic Patch: A Multifunctional Microneedle Platform for Combinatorial Mild Hyperthermia with Immunotherapy in Breast Cancer., PMID:40527606

Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation., PMID:40527320

Multifunctional Nanoplatform for Highly Accurate Profiling of Triple-Negative Breast Cancer-Derived Chemo- and Immunotherapy Resistance Exosomes., PMID:40526975

Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial., PMID:40526879

IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia., PMID:40526840

Precise PEGylation Modulates the in Vivo Fate of Peptide Radiopharmaceuticals., PMID:40525701

An Anisotropic Gold-Palladium Heterostructured Nanosystem for Synergistically Overcoming Radioresistance and Enhancing Melanoma Radioimmunotherapy., PMID:40525676

Engineering TLR7/8 Agonist-Loaded and Tumor-Anchored Gold Nanosensitizers for Enhanced Radioimmunotherapy., PMID:40525673

A Multimodal Nanoplatform Integrating Photodynamic Therapy and Wnt/β-Catenin Inhibition Reprograms the Tumor Microenvironment to Potentiate Immune Checkpoint Therapy in Triple-Negative Breast Cancer., PMID:40525603

Systematic Pan-Cancer Analysis of the Oncogenic and Immunological Function of Stanniocalcin-1 (STC1)., PMID:40525442

Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial., PMID:40524802

Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real-World Study., PMID:40524516

An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn2+ overload triggered pyroptosis., PMID:40524159

Datasheet
$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-Mouse PD-L1 & OX40 Bispecific Antibody (Iv0244) [VME43201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only